Evaluation of Orexin A and Orexin B Levels after Bariatric Surgery in Patient with Obesity
- 17 March 2026
- journal article
- Published by Cukurova Anestezi ve Cerrahi Bilimler Dergisi in Cukurova Anestezi ve Cerrahi Bilimler Dergisi
- Vol. 9 (1) , 6-11
Abstract
This study aimed to evaluate the changes in serum Orexin A and B levels following laparoscopic sleeve gastrectomy (LSG) in patients with obesity. Methods: Thirty obese patients undergoing LSG were evaluated at baseline, 3 months, and 6 months postoperatively for Orexin A and B levels and BMI. Results: A significant reduction in BMI was observed at postoperative 3 and 6 months (p < 0.001). Orexin B levels significantly declined at 6 months compared to preoperative and 3-month values (p = 0.002), while changes in Orexin A were not statistically significant. No correlation was found between orexin levels and BMI. Conclusions: Postoperative reductions in Orexin B may reflect a role in appetite regulation following bariatric surgery. These findings support further investigation into orexin-targeted therapies in obesity management. Methods: Preoperative, postoperative 3rd, and 6th-month venous blood samples were collected from 30 obese patients diagnosed with obesity and undergoing LSG to measure Orexin A and B levels. The obtained values and body maSD indexes (BMI) calculated at the same time intervals were compared. This study was approved by the Clinical Research Ethics Committee of the University of Health Sciences Antalya Training and Research Hospital (Approval Date: August 5, 2021; Approval No: 11/10) and was conducted in accordance with the Declaration of Helsinki. Conclusions: Previous experimental studies have shown that Orexin peptides are activated in the fasting state and play an active role in obesity by increasing food intake. In this study, we found that Orexin B levels were significantly reduced in patients who experienced weight loss. We believe that monitoring Orexin levels can be beneficial in the treatment of obesity, and inhibiting its activity at the hypothalamic level can contribute to the treatment by reducing food intake. Conducting new studies with a larger number of patients and longer follow-up periods will lead to radical and effective changes in the treatment of obesity.Keywords
This publication has 33 references indexed in Scilit:
- Laparoscopic sleeve gastrectomy for weight loss and treatment of type 2 diabetes mellitusJournal of Taibah University Medical Sciences, 2021
- Orexin/hypocretin and dysregulated eating: Promotion of foraging behaviorBrain Research, 2020
- Orexin Receptor Antagonists as Emerging Treatments for Psychiatric DisordersNeuroscience Bulletin, 2019
- Differential Roles of Each Orexin Receptor Signaling in ObesityiScience, 2019
- Increased Number and Activity of a Lateral Subpopulation of Hypothalamic Orexin/Hypocretin Neurons Underlies the Expression of an Addicted State in RatsBiological Psychiatry, 2019
- Spontaneous Physical Activity Defends Against ObesityCurrent Obesity Reports, 2017
- The Epidemiology of Obesity: A Big PicturePharmacoEconomics, 2014
- Circadian system, sleep and endocrinologyMolecular and Cellular Endocrinology, 2012
- Energy Expenditure2012
- Enhanced Orexin Receptor-2 Signaling Prevents Diet-Induced Obesity and Improves Leptin SensitivityCell Metabolism, 2009